Disease modifying treatment trials in Parkinson’s disease: how to balance expectations and interests of patients, physicians and industry partners?

por Berg, D., Eggert, K., Haslinger, B., Kassubek, J., Mollenhauer, B., Reetz, K., Rogge, A., Schaeffer, E., Tönges, L., Zeuner, K. E.
Publicado 2020

Basic clinical features do not predict dopamine transporter binding in idiopathic REM behavior disorder

por Chahine, L. M., Iranzo, A., Fernández-Arcos, A., Simuni, T., Seedorff, N., Caspell-Garcia, C., Amara, A. W., Comella, C., Högl, B., Hamilton, J., Marek, K., Mayer, G., Mollenhauer, B., Postuma, R., Tolosa, E., Trenkwalder, C., Videnovic, A., Oertel, W.
Publicado 2019

Identification of distinct pathological signatures induced by patient-derived α-synuclein structures in nonhuman primates

por Bourdenx, M., Nioche, A., Dovero, S., Arotcarena, M.-L., Camus, S., Porras, G., Thiolat, M.-L., Rougier, N. P., Prigent, A., Aubert, P., Bohic, S., Sandt, C., Laferrière, F., Doudnikoff, E., Kruse, N., Mollenhauer, B., Novello, S., Morari, M., Leste-Lasserre, T., Trigo-Damas, I., Goillandeau, M., Perier, C., Estrada, C., Garcia-Carrillo, N., Recasens, A., Vaikath, N. N., El-Agnaf, O. M. A., Herrero, M. T., Derkinderen, P., Vila, M., Obeso, J. A., Dehay, B., Bezard, E.
Publicado 2020